CDK4 and breast carcinoma: Therefore, our study used the non-PH model to conduct NMA on the effectiveness of CDK4/6 inhibitors in the first-line treatment of HR + advanced breast cancer, and directly used survival time instead of HR as an efficacy indicator to more intuitively express the results.